In vivo effect of oracin on doxorubicin reduction, biodistribution and efficacy in Ehrlich tumor bearing mice

Pharmacological Reports

Volumn 65, Issue 2, 2013, Pages 445-452

  Hanušová, Veronika ^a   Tomšík, Pavel ^b   Kriesfalusyová, Lenka ^b   Pakostová, Alena ^a   Boušová, Iva ^a   Skálová, Lenka ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Carbonyl reduction; CBR1; Doxorubicin pharmacokinetics; Doxorubicinol

Indexed keywords

DOXORUBICIN; ORACIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; ENZYME INHIBITION; FEMALE; HEART; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 84879389507     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71020-X     Document Type: Article

References (27)

1. Adamcova M, Gersl V, Hrdina R, Melka M, Mazurova Y, Vavrova J: Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol, 1999, 125, 268-274.
2. Ax W, Soldan M, Koch L, Maser E: Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol, 2000, 59, 293-300.
3. Awara WM, El-Sisi AE, El-Sayad ME, Goda AE: The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour, does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol Res, 2004, 50, 487-498.
4. Bast A, Kaiserová H, Hartog G, Haenen G, Vijgh W: Protectors against doxorubicin induced cardiotoxicity, flavonoids. Cell Biol Toxicol, 2007, 23, 39-47.
5. Bibby DC, Talmadge JE, Dalal MK, Kurz SG, Chytil KM, Barry SE, Shand DG, Steiert M: Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharm, 2005, 293, 281-290.
6. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI: Doxorubicin, the good, the bad and the ugly effect. Curr Med Chem, 2009, 16, 3267-3285.
7. Céspedes MV, Casanova I, Parreño M, Mangues R: Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol, 2006, 8, 318-29
8. Erenpreisa J, Cragg MS: Mitotic death, a mechanism of survival? A review. Cancer Cell Int, 2001, 1, 1-15
9. Gavelova M, Hladikova J, Vildova L, Novotna R, Vondracek J, Krcmar P, Machal M, Skalova L : Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem Biol Interact, 2008, 176, 9-18.
10. Gersl V, Mazurova Y, Bajgar J, Melka M, Hrdina R, Palicka V: Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline, comparison with daunorubicin in rabbits. Arch Toxicol, 1996, 70, 645-651.
11. Gonzalez-Covarrubias V, Kalabus JL, Blanco JG: Inhibition of polymorphic human carbonyl reductase 1 :CBR1 by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER). Pharm Res, 2008, 25, 1730-1734.
12. Hanusova V, Bousova I, Pakostova A, Skalova L: The influence of oracin on reduction and toxicity of doxorubicin in hepatocytes and mammary epithelial cells MCF-10A. Xenobiotica, 2012, 42, 571-579.
13. Hanusova V, Bousova I, Skalova L: Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. Drug Metab Rev, 2011, 43, 540-557.
14. Hanusova V, Kralova V, Schroterova L, Trilecova L, Pakostova A, Skalova L: The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells. Xenobiotica, 2010, 40, 681-690.
15. Kalender S, Kalender Y, Ates A, Yel M, Olcay E, Candan S: Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats. Braz J Med Biol Res, 2002, 35, 1379-1387.
16. Kassner N, Huse K, Martin HJ, Godtel-Armbrust U, Metzger A, Meineke I: Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos, 2008, 36, 2113-2120.
17. Klein HO, Toermer HJ, Christian E, Coerper C, Lennartz KJ, Akokan G: Experimental investigations on a sequential combination chemotherapy protocol. J Cancer Res Clin Oncol, 1980, 96, 65-78.
18. Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, Meucci E: Anthracycline secondary alcohol metabolite formation in human or rabbit heart, biochemical aspects and pharmacologic implications. Biochem Pharmacol, 2003, 66, 989-998
19. Olson RD, Mushlin PS, Brenner MD, Fleischer S, Cusack BJ, Chang BK, Boucek RJ Jr.: Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA, 1988, 85, 3585-3589.
20. Oppermann U: Carbonyl reductases, the complex relationships of mammalian carbonyl-And quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol, 2007, 47, 293-322.
21. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ: Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev, 2004, 30, 181-191
22. Segura JA, Barbero LG, Márquez J: Early tumor effect on splenic Th lymphocytes in mice. FEBS Lett, 1997, 414, 1-6.
23. Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, De CJ et al.: Cardiac toxicity, old and new issues in anti-cancer drugs. Clin Transl Oncol, 2008, 10, 35-46.
24. Singal P K, Li T, Kumar D, Danelisen I, Iliskovic N: Adriamycin-induced heartfailure, mechanism and modulation. Mol Cell Biochem, 2000, 207, 77-85.
25. Skarydova L, Skarka A, Novotna R, Zivna L, Martin HJ, Wsol V: Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin. Toxicology, 2009, 264, 52-60.
26. Teicher BA: Tumor Models in Cancer Research, 2nd edn., Humana Press, Totowa, 2010, 47.
27. Vaclavikova R, Kondrova E, Ehrlichova M, Boumendjel A, Kovar J, Stopka P: The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorg Med Chem, 2008, 16, 2034-2042.